Saniona Revenue and Competitors
Estimated Revenue & Valuation
- Saniona's estimated annual revenue is currently $7.6M per year.
- Saniona's estimated revenue per employee is $201,000
Employee Data
- Saniona has 38 Employees.
- Saniona grew their employee count by 9% last year.
Saniona's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Development Officer (CDO) | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | SVP, Research | Reveal Email/Phone |
5 | Director In Vitro Pharmacology | Reveal Email/Phone |
6 | Director ADME | Reveal Email/Phone |
7 | Director Invivo Pharmacology | Reveal Email/Phone |
8 | Project Director, Medicinal Chemistry | Reveal Email/Phone |
9 | Laborant | Reveal Email/Phone |
10 | Senior Research Assistant | Reveal Email/Phone |
Saniona Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Saniona?
Saniona is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline features SAN711, a Phase 2-ready candidate drug targeting absence seizures, SAN2219 for acute repetitive seizures, and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine, Saniona’s most advanced candidate, is progressing towards regulatory approval for obesity in Mexico through a partnership with Medix. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona has esteemed partners, including Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, please visit www.saniona.com (OMX: SANION).
keywords:N/A
N/A
Total Funding
38
Number of Employees
$7.6M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.4M | 38 | 31% | N/A |
#2 | $4.4M | 38 | N/A | N/A |
#3 | $9.3M | 38 | N/A | N/A |
#4 | $4.4M | 38 | N/A | N/A |
#5 | $7.7M | 38 | N/A | N/A |